NASDAQ: IMRX
Immuneering Corporation
Healthcare · Biotechnology
Market Cap
$160.09M
52w High
$10.08
52w Low
$2.29
P/E
-3.57
Volume
1.00M
Outstanding Shares
36.30M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 59.21% over the last year. Free cash flow grew 6.96% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
7
Buy
4
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 12, 2026
Q3 FY26 · EPS est -$0.26 · Revenue est —
View